Navigation Links
CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
Date:6/11/2008

valuating CR011- vcMMAE in patients with advanced melanoma utilizes a Simon 2-Stage design with a primary endpoint of objective response rate. Patients enrolled in the study may have received no more than one prior cytotoxic regimen, but may have received an unlimited number of prior cytokine, immune or vaccine therapies. Enrollment in the study is expected to be completed by the end of 2008.

CR011-vcMMAE targets a protein known as GPNMB, which has been shown to be overexpressed in melanoma, breast cancer and brain tumors. Based on the clinical activity observed in the treatment of melanoma, CuraGen anticipates initiating a Phase II trial evaluating CR011-vcMMAE for the treatment of patients with metastatic breast cancer in the third quarter of 2008. Furthermore, CuraGen is conducting preclinical research to determine the optimal approach for utilizing CR011-vcMMAE as a potential treatment of brain tumors, including glioblastoma multiforme.

CR011-vcMMAE is an antibody-drug conjugate (ADC) comprised of a fully- human monoclonal antibody against glycoprotein NMB (GPNMB) attached to a potent, synthetic drug monomethyl auristatin E (MMAE), using Seattle Genetics' proprietary technology. GPNMB is a novel, selective target that plays a role in the ability of cancer cells to invade and metastasize. CR011-vcMMAE contains an enzyme-cleavable linker designed to be stable in the bloodstream and to release MMAE after internalization into tumor cells that express GPNMB, resulting in cancer cell death.

About Melanoma

The number of people diagnosed with melanoma is rapidly increasing. It is expected that approximately 60,000 new cases of melanoma will be diagnosed and an estimated 8,000 people in the U.S. will die of the disease during 2008. The prognosis for patients with advanced melanoma is poor, and studies have shown that the median survival is less than nine months.

About CuraGen

CuraGen Corporation (Nasdaq:

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... YORK , March 27, 2015 BioCorRx, ... Santa Ana, California is a healthcare ... for which is estimated at $22 billion in the U.S. ... the use of FDA-approved Naltrexone in a specially compounded form ... Australia and New Zealand ...
(Date:3/27/2015)... March 27, 2015 Across the global healthcare ... challenges in clinical development, market education, and regulatory compliance. ... Medical Affairs function is expected to increase in prominence ... According to research by benchmarking firm, Best ... group dedicated to Medical Affairs. Among companies in ...
(Date:3/27/2015)... 2015  The quality function within the medical device ... quality standards at every stage of the product life ... also have the challenge of balancing quality and safety ... don,t effectively balance these priorities risk funding and staffing ... and regulatory scrutiny. For the third consecutive ...
Breaking Medicine Technology:Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2Medical Affairs Capabilities Expanding in Emerging Marketplaces 2New Medical Device Quality Study Finds Regulatory Environment is Boosting Quality Spending, Especially for Large Companies 2
... Clinical trials in which participants are randomly assigned to different ... conducted correctly, it,s widely accepted by the research community that ... But researchers at the University of Michigan hope to ... patients by investigating the impact of a class of innovative ...
... CRY ), an implantable biological medical device ... BioGlue Surgical Adhesive has received Shonin approval from the ... use in the repair of aortic dissections. ... in Japan for use in this subset of cardiac ...
Cached Medicine Technology:U-M Receives NIH, FDA Grant To Study Adaptive Clinical Trial Design 2CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive 2CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive 3CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive 4CryoLife Receives Japanese Regulatory Approval for BioGlue Surgical Adhesive 5
(Date:3/28/2015)... AZ (PRWEB) March 28, 2015 Coffee could ... also help protect you from gum disease, researchers have found. ... against gum disease. , Coffee contains antioxidants. Antioxidants fight gum ... the question researchers at Boston Univ. Henry M. Goldman School ... in the August 2014 issue of the Journal of Periodontology. ...
(Date:3/28/2015)... March 28, 2015 Could genetic code ... new study by researchers at the Harvard ... with the support of the Coffee and Caffeine Genetics ... Psychiatry this past fall, the study—one of several recent ... genomic data from more than 120,000 regular coffee drinkers ...
(Date:3/28/2015)... "Necrorun" was featured on NewsWatch as part ... the latest and coolest applications on the market for ... NewsWatch and technology expert, conducted the app review and ... runner game with knights, nature, and peasants. , ... according to Eurogamer. The popularity of these games grew ...
(Date:3/28/2015)... Take a bite of warm, gooey pepperoni ... tumble into the stomach, ready to break down your ... these acids run amok, triggering a burning sensation in ... than 60 million Americans have heartburn at least once ... and how it can be stopped. , Heartburn or ...
(Date:3/28/2015)... 28, 2015 With more than ... fields of osteoporosis, osteoarthritis and musculoskeletal diseases gathered ... may be the first time in the 17-year ... that the hot-button topic is an emerging non-pharmaceutical ... well-accepted scientific principles of Wolff’s law, osteogenic loading ...
Breaking Medicine News(10 mins):Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Bypass Your Heartburn Worries This Easter With Tylers Coffee 2Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2
... BeneChill, Inc. ( www.benechill.com ) today announced the ... study. This randomized study will determine whether intra-nasal ... patient resuscitation and survival rates.The PRINCE study is ... Europe. The company received CE marking for the ...
... manufacturer of,GUM(R) and Butler(R) brand products and a leader ... worldwide, is putting its support,behind the American Dental Association,s ... health. , Each February since ... to raise awareness about the importance of oral health. ...
... most symptoms fade within 6 weeks, experts say , , ... physical therapy and anti-inflammatory drugs is the most effective ... degenerative disc disease, according to a review of published ... 90 percent of people with low back pain, symptoms ...
... part in regular physical activity have a better quality ... issue of the journal Cancer Epidemiology Biomarkers and ... more physically active report better mood, more vigor, and ... take-home message is that early-stage lung cancer survivors may ...
... ANN ARBOR, Mich. One-fifth of women who should ... potentially lifesaving treatment, according to a new study from ... , The study looked at 396 women who were ... found that 19 percent of women who fell clearly ...
... Vitamin(R) has launched the web site for Keep ,Em ... that gives pregnant women the greatest opportunity to carry ... information and offering online community support. , ... Cookin, with one very specific goal in mind --- ...
Cached Medicine News:Health News:BeneChill Launches European Study of Intra-Arrest Cooling 2Health News:Sunstar to Support ADA's 60th Annual National Children's Dental Health Month 2Health News:Sunstar to Support ADA's 60th Annual National Children's Dental Health Month 3Health News:Therapy, Meds Best for Lumbar Low Back Pain 2Health News:Regular physical activity linked to better quality of life in early-stage lung cancer survivors 2Health News:19 percent of breast cancer patients don’t receive recommended radiation after mastectomy 2Health News:Vitamin Launches Online Face for Keep 'Em Cookin' 2
Benchtop UV Incubator is designed to provide precise temperature control and uniformity throughout the chamber. Decontaminate chamber between experiments with built-in shortwave UV....
Inquire...
Inquire...
Inquire...
Medicine Products: